Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety

  • O. Weinreb
  • T. Amit
  • O. Bar-Am
  • Y. Sagi
  • S. Mandel
  • M. B. H. Youdim
Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 70)


Our recent studies aimed to elucidate the molecular and biochemical mechanism of actions of the novel anti-Parkinson’s drug, rasagiline, an irreversible and selective monoamine oxidase (MAO)-B inhibitor and its propargyl moiety, propargylamine. In cell death models induced by serum withdrawal in rat PC12 cells and human SH-SY5Y neuroblastoma cells, both rasagiline and propargylamine exerted neuroprotective and neurorescue activities via multiple survival pathways, including: stimulation of protein kinase C (PKC) phosphorylation; up-regulation of protein and gene levels of PKCα, PKCɛ and the anti-apoptotic Bcl-2, Bcl-xL, and Bcl-w; and up-regulation of the neurotrophic factors, BDNF and GDNF mRNAs. Rasagiline and propargylamine inhibited the cleavage and subsequent activation of procaspase- 3 and poly ADP-ribose polymerase. Additionally, these compounds significantly down-regulated PKCγ mRNA and decreased the level of the pro-apoptotic proteins, Bax, Bad, Bim and H2A.X. Rasagiline and propargylamine both regulated amyloid precursor protein (APP) processing towards the nonamyloidogenic pathway. These structure-activity studies have provided evidence that propargylamine promoted neuronal survival via neuroprotective/neurorescue pathways similar to that of rasagiline. In addition, recent study demonstrated that chronic low doses of rasagiline administered to mice subsequently to 1 methyl–4 phenyl 1,2,3,6 tetrahydropyridine (MPTP), rescued dopaminergic neurons in the substantia nigra pars compacta via activation of the Ras-PI3K-Akt survival pathway, suggesting that rasagiline may possess a disease modifying activity.


PC12 Cell Amyloid Precursor Protein Parkinson Study Group Rasagiline Mesylate Propargyl Moiety 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326PubMedCrossRefGoogle Scholar
  2. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)-salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82: 913–923PubMedCrossRefGoogle Scholar
  3. Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors and APP processing in the neurorescue activity of popargylamine. FASEB J 19: 1899–1901PubMedGoogle Scholar
  4. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH (2004) Regulation of protein kinase C by the anti-Parkinsondrug, MAO-Binhibitor, rasagilineand its derivatives in vivo. J Neurochem 89: 1119–1125PubMedCrossRefGoogle Scholar
  5. Bernardi P, Petronilli V, Di Lisa F, Forte M (2001) A mitochondrial perspective on cell death. Trends Biochem Sci 26: 112–117PubMedCrossRefGoogle Scholar
  6. Blandini F (2005) Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease? CNS Drug Rev 11: 183–194PubMedCrossRefGoogle Scholar
  7. Bush AI (2003) The metallobiology of Alzheimer’s disease. Trends Neurosci 26: 207–214PubMedCrossRefGoogle Scholar
  8. Chen JJ, Swope DM (2005) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878–894PubMedCrossRefGoogle Scholar
  9. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ (2001) BCL-2, BCLX(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705–711PubMedCrossRefGoogle Scholar
  10. Cory S, Adams JM (2002) The Bcl2 family: regulator of the cellular life-or-death switch. Nature Reviews Cancer 2: 647–656PubMedCrossRefGoogle Scholar
  11. Evan G, Littlewood T (1998) A matter of life and cell death. Science 281: 1317–1322PubMedCrossRefGoogle Scholar
  12. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 80: 495–499PubMedGoogle Scholar
  13. Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schachtele C, Klemm K, Grunicke H (1996) Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 74: 897–905PubMedGoogle Scholar
  14. Gubina E, Rinaudo MS, Szallasi Z, Blumberg PM, Mufson RA (1998) Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood 91: 823–829PubMedGoogle Scholar
  15. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH (1985) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 116: 313–317PubMedCrossRefGoogle Scholar
  16. Hsieh YC, Jao HC, Yang RC, Hsu HK, Hsu C (2003) Suppression of protein kinase Calpha triggers apoptosis through down-regulation of Bcl-xL in a rat hepatic epithelial cell line. Shock 19: 582–587PubMedCrossRefGoogle Scholar
  17. Huang W, Chen Y, Shohami E, Weinstock M (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 366: 127–135PubMedCrossRefGoogle Scholar
  18. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6: 513–519PubMedCrossRefGoogle Scholar
  19. Ku WC, Cheng AJ, Wang TC (1997) Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun 241: 730–736PubMedCrossRefGoogle Scholar
  20. Maruyama W, Akao Y, Youdim MBH, Naoi M (2000a) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J Neural Transm [Suppl]: 171–186Google Scholar
  21. Maruyama W, Youdim MBH, Naoi M (2000b) Antiapoptotic function of N-propargylamine-1(R)-and (S)-aminoindan, Rasagiline and TV1022. Ann NY Acad Sci 939: 320–329CrossRefGoogle Scholar
  22. Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M (2001a) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78: 727–735PubMedCrossRefGoogle Scholar
  23. Maruyama W, Youdim MBH, Naoi M (2001b) Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann NY Acad Sci 939: 320–329PubMedCrossRefGoogle Scholar
  24. Maruyama W, Akao Y, Carrillo M, Kitani K, Youdim M, Naoi M (2002a) Neuroprotection by propargylamines in Parkinson’s disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24: 675–682PubMedCrossRefGoogle Scholar
  25. Maruyama W, Takahashi T, Youdim MBH, Naoi M (2002b) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109: 467–481PubMedCrossRefGoogle Scholar
  26. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim MBH, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44: 393–400PubMedCrossRefGoogle Scholar
  27. Mills J, Reiner PB (1999) Regulation of amyloid precursor protein cleavage. J Neurochem 72: 443–460PubMedCrossRefGoogle Scholar
  28. Murer MG, Yan Q, Raisman-Vozari R (2001) Brainderived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63: 71–124PubMedCrossRefGoogle Scholar
  29. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566CrossRefGoogle Scholar
  30. Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248CrossRefGoogle Scholar
  31. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G (2000) Rasagiline mesylate, a new MAOB inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23: 324–330PubMedCrossRefGoogle Scholar
  32. Ruvolo PP, Deng X, Carr BK, May WS (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273: 25436–25442PubMedCrossRefGoogle Scholar
  33. Sagi Y, Mandel S, Youdim MBH (2005) Neurorescue activity of rasagiline involves activation of the Ras-Phosphoinositol 3 kinase-Akt survival pathway in the MPTP mouse model of Parkinson’s disease. Parkinsonism Relat Disord 11[Suppl]: 192Google Scholar
  34. Speiser Z, Mayk A, Eliash S, Cohen S (1999) Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 106: 593–606PubMedCrossRefGoogle Scholar
  35. Tan Y, Ruan HD et al. (1999) p90(RSK) blocks badmediated cell death via a protein kinase C-dependent pathway. J Biol Chem: 34859–34867Google Scholar
  36. Turner PR, O’Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1–32PubMedCrossRefGoogle Scholar
  37. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease. Gene Ther 9: 381–389PubMedCrossRefGoogle Scholar
  38. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18: 1471–1473PubMedGoogle Scholar
  39. Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MBH (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16: 1674–1666PubMedGoogle Scholar
  40. Yogev-Falach M, Amit T, Bar-AM O, Youdim MBH (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17: 2325–2327PubMedGoogle Scholar
  41. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79: 172–179PubMedCrossRefGoogle Scholar
  42. Youdim MB, Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27–35PubMedCrossRefGoogle Scholar
  43. Youdim MBH (1991) PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla. J Neural Transm [Suppl 34]: 61–67Google Scholar
  44. Youdim MBH (2003) Rasagiline: an anti-Parkinson drug with neuroprotective activity. Future Drugs 3: 737–749Google Scholar
  45. Youdim MBH, Amit T, Yogev-Falach M, Bar-Am O, Maruyama W, Naoi M (2003) The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-parkinson drug, rasagiline. Biochem Pharmacol 66: 1635–1641PubMedCrossRefGoogle Scholar
  46. Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500–506PubMedCrossRefGoogle Scholar
  47. Youdim MBH, Weinstock M (2002) Molecular basis of neuroprotective activities of rasagiline and the anti alzheimer drug, TV3326, [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate]. Cell Mol Neurobiol 21: 555–573CrossRefGoogle Scholar
  48. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G (1998) Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16: 2265–2282PubMedCrossRefGoogle Scholar
  49. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863–873PubMedCrossRefGoogle Scholar
  50. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005a) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68–78PubMedCrossRefGoogle Scholar
  51. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M (2005b) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg Med Chem 13: 773–783PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • O. Weinreb
    • 1
  • T. Amit
    • 1
  • O. Bar-Am
    • 1
  • Y. Sagi
    • 1
  • S. Mandel
    • 1
  • M. B. H. Youdim
    • 1
  1. 1.Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of PharmacologyRappaport Family Research Institute, Technion-Faculty of MedicineHaifaIsrael

Personalised recommendations